Stock NGNE NEUROGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
37.6 USD +10.49% Intraday chart for Neurogene Inc. +17.10% +94.01%
May. 10 Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting CI

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 248.5 488.1 - -
Enterprise Value (EV) 1 51.47 161 -13.04 488.1
P/E ratio -2.49 x -10.3 x -10.5 x -8.83 x
Yield - - - -
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA - - - -
EV / FCF -0.99 x -2.33 x 0.17 x -5.88 x
FCF Yield -101% -42.9% 583% -17%
Price to Book - - - -
Nbr of stocks (in thousands) 12,824 12,980 - -
Reference price 2 19.38 37.60 37.60 37.60
Announcement Date 3/18/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - - - - -
EBITDA - - - - -
EBIT 1 - -55.58 -65.55 -78.27 -86.1
Operating Margin - - - - -
Earnings before Tax (EBT) 1 - -36.32 -56.89 -75.62 -
Net income 1 -55.19 -36.32 -66.1 -76.91 -88.15
Net margin - - - - -
EPS 2 -10.58 -7.798 -3.654 -3.588 -4.260
Free Cash Flow 1 - -51.74 -69 -76 -83
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 11/8/23 3/18/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - -
EBITDA - - - - - -
EBIT 1 -14.73 -18.78 -16.08 -16.72 -17.38 -
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 2.383 -16.92 -13.9 -14.54 -15.17 -
Net income 1 2.383 -16.92 -15.58 -16.41 -17.07 -
Net margin - - - - - -
EPS 2 - -1.000 -0.9300 -0.9720 -0.8840 -0.9900
Dividend per Share - - - - - -
Announcement Date 3/18/24 5/10/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 - - - - -
Net Cash position 1 - 197 327 501 -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - -51.7 -69 -76 -83
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 1 - 0.32 1.5 1.1 -
Capex / Sales - - - - -
Announcement Date 11/8/23 3/18/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
37.6 USD
Average target price
51.25 USD
Spread / Average Target
+36.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NEUROGENE INC. Stock Neurogene Inc.
+94.01% 488M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NGNE Stock
  4. Financials Neurogene Inc.